215 related articles for article (PubMed ID: 12435168)
1. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
Henry DH
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
[TBL] [Abstract][Full Text] [Related]
2. Anemia in cancer patients: significance, epidemiology, and current therapy.
Tchekmedyian NS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
[TBL] [Abstract][Full Text] [Related]
3. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
Pirker R
Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
[TBL] [Abstract][Full Text] [Related]
4. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
7. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
[TBL] [Abstract][Full Text] [Related]
8. Darbepoetin alpha coming of age.
Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa: a review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy.
Siddiqui MA; Keating GM
Drugs; 2006; 66(7):997-1012. PubMed ID: 16740021
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
12. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
Glaspy JA
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
[TBL] [Abstract][Full Text] [Related]
13. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
Crawford J
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
Glaspy J
Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
Vansteenkiste J; Wauters I
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
Vansteenkiste J; Rossi G; Foote M
Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
20. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
Folloder J
Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
